Date 25 Apr 2022


BenevolentAI utilizes AI technologies for medicine discovery. The firm has over 20 various drug studies in the pipeline. HQ - London.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
  • Combo news

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
$  Share Price


Goldman SachsGoldman Sachs
Woodford Investment ManagementWoodford Investment Management
Upsher Smith LaboratoriesUpsher Smith Laboratories
Lansdowne PartnersLansdowne Partners
Temasek HoldingsTemasek Holdings

News related to BenevolentAI

BenevolentAIBenevolentAI • 25 Apr 2022

BenevolentAI Begins Trading On Euronext Amsterdam - Benzinga

BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company headquartered in London, with a research facility in Cambridge (UK) and an office in ...
BenevolentAIBenevolentAI • 14 Jan 2022

BenevolentAI announces 3-year collaboration expansion with ...

The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify ...
BenevolentAIBenevolentAI • 23 Dec 2021

Pharmaceutical AI Platform and Software Global Market Insights ...

BenevolentAI. Atomwise. AI Therapeutics. Insilico Medicine. Recursion Pharmaceuticals. Lantern Pharma. Adaptive Biotechnologies....
More (28)

BenevolentAI Twitter